Page last updated: 2024-08-24

imiquimod and Fatigue

imiquimod has been researched along with Fatigue in 4 studies

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	3 (75.00)	29.6817
2010's	1 (25.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Belkoff, LH; Belldegrun, AS; Chamie, K; Donin, NM; Hakim, G; Holden, S; Holldack, J; Karsh, LI; Kivlin, D; Lamm, DL; Lenis, AT; Pantuck, AJ; Pozzi, R; Reddy, M; Shore, N	1
Dalrymple, J; Hanger, C; Hepburn, D	1
Jorizzo, JL; Neville, JA; Williford, PM	1

Trials

2 trial(s) available for imiquimod and Fatigue

Article	Year
A phase 2 study of TMX-101, intravesical imiquimod, for the treatment of carcinoma in situ bladder cancer. Urologic oncology, 2017, Volume: 35, Issue:2 Topics: Administration, Intravesical; Aged; Aged, 80 and over; Aminoquinolines; Antineoplastic Agents; Carcinoma in Situ; Cytokines; Fatigue; Female; Humans; Imiquimod; Male; Middle Aged; Prospective Studies; Treatment Outcome; Urinary Bladder Neoplasms	2017
Pilot study using topical imiquimod 5% cream in the treatment of nodular basal cell carcinoma after initial treatment with curettage. Journal of drugs in dermatology : JDD, 2007, Volume: 6, Issue:9 Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Aminoquinolines; Antineoplastic Agents; Carcinoma, Basal Cell; Curettage; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Female; Headache; Humans; Imiquimod; Male; Middle Aged; Ointments; Pilot Projects; Skin Neoplasms; Treatment Outcome	2007

Article

Year

A phase 2 study of TMX-101, intravesical imiquimod, for the treatment of carcinoma in situ bladder cancer.

Urologic oncology, 2017, Volume: 35, Issue:2

Topics: Administration, Intravesical; Aged; Aged, 80 and over; Aminoquinolines; Antineoplastic Agents; Carcinoma in Situ; Cytokines; Fatigue; Female; Humans; Imiquimod; Male; Middle Aged; Prospective Studies; Treatment Outcome; Urinary Bladder Neoplasms

2017

Pilot study using topical imiquimod 5% cream in the treatment of nodular basal cell carcinoma after initial treatment with curettage.

Journal of drugs in dermatology : JDD, 2007, Volume: 6, Issue:9

Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Aminoquinolines; Antineoplastic Agents; Carcinoma, Basal Cell; Curettage; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Female; Headache; Humans; Imiquimod; Male; Middle Aged; Ointments; Pilot Projects; Skin Neoplasms; Treatment Outcome

2007

Other Studies

2 other study(ies) available for imiquimod and Fatigue

Article	Year
Systemic reactions to imiquimod (Aldara). The Medical letter on drugs and therapeutics, 2004, Nov-08, Volume: 46, Issue:1195 Topics: Administration, Topical; Aminoquinolines; Fatigue; Humans; Imiquimod; Photosensitivity Disorders	2004
Systemic side effects from topical imiquimod. The New Zealand medical journal, 2005, Oct-07, Volume: 118, Issue:1223 Topics: Administration, Topical; Aged; Aminoquinolines; Antineoplastic Agents; Blood Sedimentation; Carcinoma, Basal Cell; Depression; Facial Neoplasms; Fatigue; Feeding and Eating Disorders; Humans; Hypotension, Orthostatic; Imiquimod; Male; Treatment Outcome; Weight Loss	2005